AOU Maggiore della Carità di Novara - Leucemia Acuta Mieloide

IRSTB082 – immune AML

Studio dell’immunogenicità e degli effetti immunologici degli agenti ipometilanti nella leucemia mieloide acuta

ARO-013

Phase III randomized, double-blind, placebo-controlled study investigating the efficacy of the addition of Crenolanib to salvage chemotherapy alone in subjects ≤ 75 years of age with relapsed/refractory FLT3 mutated acute myeloid leukemia

AML1819

Phase III study to assess the impact of Gemtuzumab Ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of Glasdegib as a post-transplant maintenance, in adult patients, aged 18-60 years, with previously untreated, de novo, favorable-intermediate-risk acute myeloid leukemia

Abbvie PMOS-VERO

VEnetoclax Real-World Observational study on effectivenes and treatment management in patients with newly diagnosed AML who are ineligible for intensive chemotherapy in Italy (VERO)

AML1919

A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study

IRST-204.08

Studio clinico IMPACT STREAM ‘’master framework for relapse or refractory acute myeloid leukemia Impact stream – a prospective observational study of treatment outcomes’’

AC220-168 (QUANTUM-WT)

A phase 3, double-blind, randomized, placebo-controlled trial of quizartinib administered in combination with induction and consolidation chemotherapy and administered as manteinance therapy in adult patients with newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia (QUANTUM-WT) (quizartinib or placebo plus chemotherapy in  newly diagnosed patients with FLT3-ITD negative AML) and Clinical Performance Study Plan – FLT3-ITD fragment segment analysis by capillary electrophoresis assay

ORAL-REAL

Oral Azacitidine Real-Life: observational study on effectiveness and management of manteinance with oral azacitidine in patients with acute myeloid leukemia in first complete remission

ASTX030-01

A multi-phase, pharmacokinetics, safety, and efficacy study of ASTX030 (Azacitidine e Cedazurine) as monotherapy in subjects with myeloid neoplasm or in combination with venetoclax in subjects with AML or MDS